Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 12/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337255 | 1.00 | CTSL (0.62) | CTSLMAPTGAASMN1; SMN2KDM4E | |
| SCHEMBL19051447 | 0.79 | ALDH1A1 (0.65) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL6339429 | 0.77 | CTSL (1.00) | CTSLGAAKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL6337478 | 0.77 | CTSL (1.00) | CTSLKDM4EALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL6339075 | 0.77 | CTSL (0.73) | CTSLMAPTKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL23950429 | 0.77 | L3MBTL1 (0.53) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL29712462 | 0.77 | L3MBTL1 (0.53) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL30852970 | 0.77 | L3MBTL1 (0.53) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL15956234 | 0.77 | L3MBTL1 (0.53) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL17312874 | 0.77 | L3MBTL1 (0.53) | MAPTGAASMN1; SMN2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | CTSL 6/4885MAPT 3955/4885GAA 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.